ThursdayMar 23, 2017 3:37 pm

ChineseInvestors.com, Inc. (CIIX) Set to Open California Retail Store, Launches XiBiDi Biotechnology in China

ChineseInvestors.com, Inc. (OTCQB: CIIX) is planning to open a retail store in San Gabriel, California, the same city in which the company is headquartered. The company also recently announced its new online cannabidiol (CBD) oil retail store would be operated by its newly-launched XiBiDi Biotechnology Co., Ltd subsidiary, which is headquartered in the Pudong Free-Trade Area of Shanghai, China. XiBiDi Biotechnology will focus on the online and offline sales of health products, including a range of hemp-derived food and beverages. In a news release, Warren Wang, founder and CEO of CIIX, said he was delighted with the registration and establishment…

Continue Reading

ThursdayMar 23, 2017 9:13 am

Singlepoint, Inc. (SING) CEO Greg Lambrecht Reveals High Points of Convectium Acquisition

Singlepoint, Inc. (OTC: SING), specializing in small- to mid-sized company acquisitions, recently began funding Convectium, an organization that sells equipment in the cannabis industry. There should be “more funding on the way,” according to Singlepoint CEO Greg Lambrecht, who discussed the acquisition in a recent episode of MoneyTV with Donald Baillargeon. Convectium sells machines that fill vials with oil, and it created a unique system for filling/packaging vape cartridges and disposable vape pens. These systems, and point of sale equipment, are sold at various trade shows, according to Lambrecht. In the phone interview, Lambrecht also revealed that Singlepoint is looking…

Continue Reading

WednesdayMar 22, 2017 8:30 am

Mixed Marijuana Messages from Trump Administration Make Diversification Imperative

Deciphering marijuana policy under the Trump Administration can be difficult, given differing statements by White House officials. Federal laws are at odds with a number of states that have legalized marijuana for medical and/or recreational use, and businesses like SinglePoint, Inc. (SING) (SING Profile), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Medical Marijuana, Inc. (MJNA), Cannabis Science, Inc. (CBIS) and ChineseInvestors.com, Inc. (CIIX) (CIIX Profile) operate in a manner that hedges them against certain risks of federal prohibition. On the campaign trail, then-candidate Donald Trump said of medical marijuana on Fox News: “I'm in favor of it a hundred percent.” With regard…

Continue Reading

TuesdayMar 21, 2017 3:03 pm

India Globalization Capital, Inc. (NYSE: IGC) Pioneering New Phytocannabinoid Products

Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses. Scientific research shows that phytocannabinoids, cannabinoids that occur naturally in the cannabis plant, are effective at relieving convulsions, seizures, anxiety, nausea, and inflammation. From fighting glaucoma to controlling epileptic seizures and easing pain, scientific research has repeatedly shown the efficacy of medicinal marijuana. Due to government misclassification of cannabis as a Schedule 1 drug, there has been only marginal progress…

Continue Reading

ThursdayMar 16, 2017 1:58 pm

ChineseInvestors.com (CIIX) Helping Treat Patients with Amyotrophic Lateral Sclerosis

Late February, a study was released (http://nnw.fm/R2CEp) reviewing evidence that supports the use of cannabinoids to treat Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others. Currently, ALS is treated with riluzole, a drug that controls neuronal signaling, but this drug does not cure the disease and can only slightly increase the chance of survival. With more effective therapeutic options…

Continue Reading

ThursdayMar 16, 2017 1:15 pm

InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in the early 2000s, and, since then, efforts to find a cure have not born fruit, with most research and development focusing instead on addressing the symptoms, such as reducing blistering and swelling and preventing wounds and pain. However, a new product currently in development by…

Continue Reading

ThursdayMar 16, 2017 8:30 am

Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (ZYNE), OWC Pharmaceutical Research Corp. (OWCP), Insys Therapeutics, Inc. (INSY) and GW Pharmaceuticals plc (GWPH) are carving lanes of unprecedented opportunities in the…

Continue Reading

WednesdayMar 15, 2017 12:30 pm

22nd Century Group, Inc. (NYSE: XXII) Starts Presentation at 29th Annual ROTH Conference

22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company’s website at www.xxiicentury.com.…

Continue Reading

WednesdayMar 15, 2017 8:30 am

“No-Touch” Approach Reduces Risk as Public Companies Tap Explosive Growth of Cannabis Industry

The marijuana industry is the new investing frontier. As a result of last November’s elections, eight states and the District of Columbia now allow the recreational use of marijuana, while another 28 states permit its use for medicinal purposes. In what has been touted as the fastest-growing industry in the U.S., investment opportunities in the cannabis space appear boundless. Companies like Singlepoint, Inc. (SING) (SING Profile), American Cannabis Company Inc. (AMMJ), General Cannabis Corp. (CANN), The Scotts Miracle-Gro Company (SMG) and Terra Tech Corp. (TRTC) are all employing a “no-touch” approach to their cannabis business models. By creating business models…

Continue Reading

WednesdayMar 15, 2017 8:30 am

Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722